Cancer Causes & Control

, Volume 7, Issue 6, pp 581–590 | Cite as

Maternal exposure to potential inhibitors of DNA topoisomerase II and infant leukemia (United States): A report from the Children's Cancer Group

  • Julie A. Ross
  • John D. Potter
  • Gregory H. Reaman
  • Thomas W. Pendergrass
  • Leslie L. Robison
Research Papers

Nearly 80 percent of infant leukemias present with an abnormality involving the MLL gene at 11q23. Moreover, secondary acute myeloid leukemias (AML) that occur as the result of chemotherapy agents, which are known to inhibit DNA topoisomerase II, often manifest the same MLL abnormalities. It has been hypothesized that de novo infant leukemias may occur as a result of maternal exposure to agents in diet and medications that inhibit DNA topoisomerase II. Three epidemiologic studies of childhood leukemia with similar methodologies were conducted in the United States and Canada over the past 10 years by the Children's Cancer Group (CCG). Of the total 771 mothers of infants diagnosed at one year of age or less (<12.5 months) who originally were interviewed (303 infant cases and 468 matched controls) across the three studies, follow-up questionnaire data on maternal exposure to potential DNA topoisomerase II inhibitors during pregnancy were available on 84 cases and 97 matched controls in the US. For maternal diet, a composite variable was created that consisted of 10 foods identified a priori as containing DNA topoisomerase II inhibitors. There were no significant trends with increasing maternal consumption for either the overall group, or the acute lymphoblastic leukemia (ALL) stratum. However, within the AML stratum, there was a statistically significant positive association (P trend=0.04) with increasing consumption of DNA topoisomerase II-inhibitor containing foods (odds ratio [OR]=9.8, 95 percent confidence interval [CI]=1.1–84.8; OR=10.2, CI=1.1–96.4; for medium and high consumption, respectively). Other potential topoisomerase II inhibitors were explored; no significant findings were found. Results of this preliminary study, in combination with molecular data, should be used in future investigations of childhood leukemia (particularly, infant) to justify the incorporation of a detailed dietary history.

Key words

Canada diet DNA topoisomerases epipodophyllotoxins infant leukemia United States 11q23 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bader, JL, Miller, RW. US cancer incidence and mortality in the first year of life. Am J Dis Child 1979; 133: 157–9.Google Scholar
  2. 2.
    Ross, JA, Davies, SM, Potter, JD, Robison, LL. Childhood leukemia with a focus on infants. Epidemiol Rev 1994; 16: 243–72.Google Scholar
  3. 3.
    Ford, AM, Ridge, SA, Cabrera, ME, et al. In utero rearrangements in the trithorax-related oncogene in infant leukemias. Nature 1993; 363: 358–60.Google Scholar
  4. 4.
    Pui, CH, Behm, FG, Raimondi, SC, et al. Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. N Engl J Med 1989; 321: 136–42.Google Scholar
  5. 5.
    Kumar, L. Epipodophyllotoxins and secondary leukemia. Lancet 1993; 342: 819–20.Google Scholar
  6. 6.
    Felix, CA, Winick, NJ, Negrini, M, Bowman, WP, Croce, CM, Lange, BJ. Common region of ALL-1 gene disrupted in epipodophyllotoxin-related secondary acute myeloid leukemia. Cancer Res 1993; 53: 2954–6.Google Scholar
  7. 7.
    Long, BH. Mechanisms of action of teniposide (VM-26) and comparison with etoposide (VP-16). Semin Oncol 1992; 19: s3-s19.Google Scholar
  8. 8.
    Gerwitz, DA. Does bulk damage to DNA explain the cytostatic and cytotoxic effects of topoisomerase II inhibitors? Biochem Pharmacol 1991; 42: 2253–8.Google Scholar
  9. 9.
    Yamashita, T, Kawada, SZ, Nakano, H. Induction of mammalian topoisomerase II dependent DNA cleavage by nonintercalative flavonoids, genistein and orobol. Biochem Pharm 1990; 39: 737–44.Google Scholar
  10. 10.
    Pierpoint, WS. Flavonoids in the human diet. In: Cody, V, MiddletonJr, E, Harborne, JB, eds. Plant Flavonoids in Biology and Medicine, Biochemical, Pharmacological, and Structure-Activity Relationships. New York, NY (USA): Alan R. Liss, Inc., 1986: 125–40.Google Scholar
  11. 11.
    Pommier, Y, Bertrand, R. The mechanisms of formation of chromosomal aberrations: role of eukaryotic DNA topoisomerases. In: Kirsch, LR, ed. The Causes and Consequences of Chromosomal Aberrations. Boca Raton, FL (USA): CRC Press, Inc., 1993: 277–309.Google Scholar
  12. 12.
    Austin, CA, Patel, S, Ono, K, Nakane, H, Fisher, LM. Sitespecific DNA cleavage by mammalian DNA topoisomerase II induced by novel flavone and catechin derivatives. Biochem J 1992; 282: 883–9.Google Scholar
  13. 13.
    Shin, CG, Strayer, JM, Wani, MA, Snapka, RM. Rapid evaluation of topoisomerase inhibitors: caffeine inhibition of topoisomerases in vivo. Teratogen Carcinog Mutagen 1990; 10: 41–52.Google Scholar
  14. 14.
    Epstein, RJ. Topoisomerases in human disease. Lancet 1988; ii: 521–3.Google Scholar
  15. 15.
    Ling, MR. Therapy of genital human papillomavirus infections. Part II: methods of treatment. Int J Dermatol 1992; 31: 769–77.Google Scholar
  16. 16.
    Ferguson, LR, Peason, A. Chromosomal changes in Chinese hamster AA8 cells caused by podophyllin, a common treatment for genital warts. Mutat Res 1992; 266: 231–9.Google Scholar
  17. 17.
    Ross, JA, Potter, JD, Robison, LL. Infant leukemia, topoisomerase II inhibitors, and the MLL gene. JNCI 1994; 86: 1678–80.Google Scholar
  18. 18.
    Robison, LL, Buckley, JD, Bunin, G. Assessment of environmental and genetic factors in the etiology of childhood cancers: The Children's Cancer Group Epidemiology Program. Environ Health Perspect 1995; 103: 111–6.Google Scholar
  19. 19.
    Shu, XO, Reaman, GH, Lampkin, B, Sather, HN, Pendergrass, TW, Robison, LL. Association of parental diagnostic x-ray exposure with risk of infant leukemia. Cancer Epidemiol Biomark Prev 1994; 3: 645–53.Google Scholar
  20. 20.
    Buckley, JD, Robison, LL, Swotinsky, R, et al. Occupational exposures of parents of children with acute nonlymphocytic leukemia: a report from the Children's Cancer Study Group. Cancer Res 1989; 49: 4030–7.Google Scholar
  21. 21.
    Robison, LL, Buckley, JD, Daigle, AE, et al. Maternal drug use and risk of childhood nonlymphoblastic leukemia among offspring. An epidemiologic investigation implicating marijuana. (A report from the Children's Cancer Study Group). Cancer 1989; 63: 1904–11.Google Scholar
  22. 22.
    Ross, JA, Severson, RK, Robison, LL, et al. Pediatric cancer in the United States: a preliminary report of a collaborative study of the Children's Cancer Group and the Pediatric Oncology Group. Cancer 1993; 71: 3415–21.Google Scholar
  23. 23.
    Robison, LL, Daigle, AE. Control selection using random digit dialing for cases of childhood cancer. Am J Epidemiol 1984; 12: 164–6.Google Scholar
  24. 24.
    Breslow, NE, Day, NE. Statistical Methods in Cancer Research. Vol. 1. The Analysis of Case-control Studies. Lyon, France: International Agency for Research on Cancer, 1980; IARC Sci. Pub. No. 32.Google Scholar
  25. 25.
    Rohan, TE, Potter, JD. Retrospective assessment of dietary intake. Am J Epidemiol 1984; 120: 876–87.Google Scholar
  26. 26.
    Jensen, OM, Wahrendorf, J, Rosenqvist, A, Geser, A. The reliability of questionnaire-derived historic dietary information and temporal stability of food habits in individuals. Am J Epidemiol 1984; 120: 281–90.Google Scholar
  27. 27.
    Lowengart, RA, Peters, JM, Cicioni, C, et al. Childhood leukemia and parents' occupational and home exposure. JNCI 1987; 79: 39–46.Google Scholar

Copyright information

© Rapid Science Publishers 1996

Authors and Affiliations

  • Julie A. Ross
  • John D. Potter
  • Gregory H. Reaman
  • Thomas W. Pendergrass
  • Leslie L. Robison

There are no affiliations available

Personalised recommendations